Preliminary effects of mobile computerized cognitive training in adults with mild cognitive impairment: interim analysis of a randomized controlled trial

Computerized cognitive training (cCT) is a non-invasive treatment strategy in which individuals repeatedly practice computer-based tasks targeting specific cognitive functions. While traditional face-to-face cognitive training is costly and accompanied by long waiting times, mobile cCT can improve the healthcare situation due to its accessibility and versatility. This interim analysis of the NeuroNation MED Effectiveness Study (NeNaE) explores the initial effects of a mobile, gamified cCT (NeuroNation MED) on cognitive and psychosocial outcomes in adults diagnosed with mild cognitive impairment (MCI; ICD-10 code F06.7). In the intention-to-treat analysis, the intervention group (IG) performed 12 weeks of training with the NeuroNation MED app, while the control group (CG) served as a waiting group. This interim analysis included the first 50 participants (IG: n = 36; CG: n = 14). The primary outcome was the index score of the Neuropsychological Assessment Battery Screening Module (S-NAB). Alpha spending resulted in an alpha level of 0.00305 for this interim analysis. This analysis provided preliminary evidence suggesting potential benefits of the intervention, with the IG demonstrating a significant improvement in the S-NAB index score (t(35) = 3.17, p = 0.0028, Cohen's d = 0.53). However, ANCOVA revealed no significant group differences between IG and CG in the S-NAB index score (F(1, 47) = 5.39, p = 0.025, η_p² = 0.125). Additionally, the IG showed a significant mean decrease in subjective cognitive failures measured by the CFQ-D (MD = -10.56, SD = 18.82, t(35) = 3.21, p = 0.0029, Cohen's d = 0.53). ANCOVA showed no significant group difference in CFQ-D post-test scores when controlling for pre-test scores (F(1, 47) = 4.81, p = 0.033, η_p² = 0.095). Analyzing the full study data is crucial to determine the effectiveness of the NeuroNation MED application for MCI.Trial registrationDRKS00025133, Date of registration: November 5, 2021.